Enhancing Global Clinical Trials: myTomorrows and Scout Team Up
myTomorrows and Scout Clinical Join Forces for Better Patient Recruitment
This innovative tech collaboration addresses emotional, logistical, and financial challenges associated with international clinical trial recruitment, ultimately accelerating access to groundbreaking treatments globally.
Streamlining Cross-Border Clinical Trials
myTomorrows, a global health technology company, has announced an exciting partnership with Scout, a leader in biopharmaceutical technology. This collaboration aims to enhance cross-border patient recruitment for clinical trials, tackling the complex financial and logistical hurdles patients often face. The partnership is set to simplify access to pre-approval treatments that might otherwise be difficult to obtain.
Cross-border clinical research encounters numerous challenges—including fragmented information systems, regulatory differences, complex visa procedures, and data privacy regulations. These obstacles, along with linguistic and cultural barriers, pose significant setbacks for communication, leading to delays in recruitment. For studies focusing on rare diseases or those with strict eligibility criteria, these impediments can extend recruitment timelines, inflate costs, and reduce patient diversity, thereby limiting access to potentially life-changing therapies.
Optimizing the Patient Journey
With this collaboration, myTomorrows and Scout are seizing the opportunity to optimize the patient journey by integrating trial matching and personalized support services. myTomorrows' Patient Navigator team will assist patients in identifying suitable trials and providing pre-screening services. Additionally, the Scout Clinical service line will offer a variety of support options including travel arrangements, expense reimbursements, and pre-funded debit cards for necessary out-of-pocket expenses. Accommodations such as short-term lodging and long-term housing will also be catered to, easing the transition for patients and their families.
Comprehensive Support for Patients and Families
Scout's CEO, Moisha Platto, stated, "Our partnership with myTomorrows is a win-win for all stakeholders across the clinical trial ecosystem. By addressing key barriers early on in the process, clinical trial sites will be able to manage international patient intake effectively and broaden their outreach. Patients will thus find a clearer understanding of the process and gain access to a wider range of potential treatment options." This emphasis on clarity and expanded access is designed to simplify enrollment, enhancing the overall experience for both patients and their families.
Revolutionizing Recruitment Outcomes
The collaboration is poised to deliver a combination of advanced logistics and precision Artificial Intelligence (AI) to revolutionize trial recruitment outcomes. By expanding the global patient reach and diversifying enrollment pools, the partnership enables researchers to more effectively meet their recruitment goals.
Simultaneously, myTomorrows’ AI platform rapidly identifies eligible trial options, achieving a remarkable 90% reduction in the time spent checking eligibility criteria for physicians compared to conventional methods. This approach not only alleviates the administrative burdens for healthcare providers but also enhances screening efficiency, leading to timely and effective recruitment while maintaining strict adherence to international data protection regulations.
Breaking Barriers in Clinical Research
Michel van Harten, MD, CEO of myTomorrows, emphasized the importance of this partnership, stating, "By removing barriers and overcoming the geographic silos usually found in traditional trials, we provide every patient—regardless of their location or personal circumstances—with a genuine opportunity to participate in clinical research. By collaborating with Scout Clinical, we aspire to make clinical research more accessible, connecting trial sites that go beyond immediate areas, whether across borders or within large domestic regions. Our innovative strategy directly addresses an industry-wide need to broaden patient access while alleviating logistical burdens for patients and their families, aiming to significantly enhance the patient journey and accelerate clinical research progress."
The Future of Global Clinical Trials
This collaboration between myTomorrows and Scout represents a significant step forward in advancing global clinical research. By ensuring that patients worldwide have better access to potentially life-altering treatments, this partnership embodies a new era in patient-oriented clinical trial recruitment.
About myTomorrows
myTomorrows is dedicated to breaking barriers for patients looking for treatment options. The company utilizes unique, proprietary technology to conduct comprehensive searches of clinical trials and, where applicable, Expanded Access Programs. With its headquarters in Amsterdam and an office in New York City, myTomorrows has assisted over 15,300 patients and 2,400 physicians across more than 240 sites in over 128 countries.
About Scout
Scout empowers the life sciences industry with a range of solutions including Scout Meetings, Scout Clinical, and Scout Academy. Their services span across face-to-face, virtual, and hybrid clinical meeting planning, and they are experts in patient payment facilitation, travel logistics, and education. Established in 1995, Scout has built a reputable foundation, ensuring regulatory compliance and consistent project delivery for leading pharmaceutical and biotechnology companies across 109 countries. Their commitment to detail and customizable service offerings has made them a trusted partner in the clinical trial landscape.
Frequently Asked Questions
What is the primary goal of the myTomorrows and Scout partnership?
The partnership aims to enhance cross-border patient recruitment for clinical trials by addressing logistical and financial challenges faced by patients.
How does the collaboration improve the patient experience?
By integrating trial matching with personalized support services, patients will receive assistance with travel, accommodations, and understanding the trial process.
What technologies are being utilized in this partnership?
The collaboration leverages advanced logistics and precision AI to streamline recruitment and reduce eligibility checking times for faster patient onboarding.
Who are the primary stakeholders involved in this initiative?
Key stakeholders include myTomorrows, Scout Clinical, clinical trial sites, patients, and their families.
What geographic areas are targeted for improved clinical trial access?
The partnership aims to facilitate access to clinical trials across borders and within large domestic regions, expanding opportunities for patients worldwide.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.